老年急性髓系白血病药物治疗进展
摘要
子靶向治疗等治疗手段的进步，AML患者的治疗疗效有所提高，但总体长期生存率仍不高。患者预后取决于多种因素，
包括年龄、遗传学改变、合并症及治疗的反应。本文综述了老年急性髓系白血病患者药物治疗的新进展，包括靶向治疗、
和免疫治疗等方面的研究进展和临床应用情况，旨在为临床医生提供最新的治疗信息和未来研究方向。
关键词
全文:
PDF参考
[1]SHALLIS R M，WANG R，DAVIDOFF A，et al.Epidemiology of acute myeloid leukemia：Recent progress and enduring
challenges[J].Blood reviews，2019，36：70-87.
[2]KAYSER S，LEVIS M J.The clinical impact of the molecular landscape of acute myeloid leukemia[J].Haematologica，2023，108（2）：308-320.
[3]SIEGEL R L，GIAQUINTO A N，JEMAL A.Cancer statistics，2024[J].CA：A Cancer Journal for Clinicians，2024，74（1）：12-49.
[4]郑荣寿，陈茹，王少明，等.2022 年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志，2024，46（3）.
[5]唐菲菲，黄晓军.老年急性髓系白血病的治疗[J].中华内科杂志，2023，62（3）.
[6]LARIBI K，SOBH M，GHEZ D，et al.Impact of age，functional status，and comorbidities on quality of life and outcomes in elderly
patients with AML：review[J].Ann Hematol，2021，100（6）：1359-1376.
[7]孟广强，陈以娟，郭慧霞，等.老年高白细胞急性髓系白血病临床特点与生存分析[J].实用医学杂志，2019，35（02）：242-246.
[8]BANG S，KANG K，SONG I，et al.Real-World Treatment Patterns and Clinical Outcomes in Korean Patients With AML Ineligible for
First-Line Intensive Chemotherapy ： A Subanalysis of the CURRENT Study ， a Non-Interventional ， Retrospective Chart
Review[J].Journal of Korean Medical Science，2023，38（44）.
[9]CARDINALE D，IACOPO F，CIPOLLA C M.Cardiotoxicity of Anthracyclines[J].Frontiers in Cardiovascular Medicine，2020，7.
[10]WANG H，XIAO X，XIAO Q，et al.The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction
therapy in acute myeloid leukemia[J].Medicine，2020，99（24）：e20094.
[11]PALMIERI R，PATERNO G，De BELLIS E，et al.Therapeutic Choice in Older Patients with Acute Myeloid Leukemia：A Matter of
Fitness[J].Cancers，2020，12（1）：120.
[12]CHOI J H，SHUKLA M，ABDUL-HAY M.Acute Myeloid Leukemia Treatment in the Elderly：A Comprehensive Review of thePresent and Future[J].Acta Haematologica，2023，146（6）：431-457.
[13]GEBRU M T，WANG H.Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia[J].Journal of
Hematology & Oncology，2020，13（1）.
[14]KIYOI H，KAWASHIMA N，ISHIKAWA Y.FLT3 mutations in acute myeloid leukemia：Therapeutic paradigm beyond inhibitor
development[J].Cancer Science，2020，111（2）：312-322.
[15]DÖHNER H，WEBER D，KRZYKALLA J，et al.Midostaurin plus intensive chemotherapy for younger and older patients with AML
and FLT3 internal tandem duplications[J].Blood Advances，2022，6（18）：5345-5355.
[16]SCHMALBROCK L K，DOLNIK A，COCCIARDI S，et al.Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under
treatment with midostaurin[J].Blood，2021，137（22）：3093-3104.
[17]马家乐，葛峥.急性髓系白血病治疗药物临床研究新进展[J].药学进展，2022，46（06）：455-470.
[18]PRATZ K W，CHERRY M，ALTMAN J K，et al.Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as
Maintenance Therapy：A Phase IB Study in Patients With Newly Diagnosed AML[J].Journal of Clinical Oncology，2023，41（26）：
4236-4246.
[19]PERL A E，LARSON R A，PODOLTSEV N A，et al.Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute
Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage
Chemotherapy[J].Transplantation and Cellular Therapy，2023，29（4）：261-265.
[20]DINARDO C D，STEIN A S，STEIN E M，et al.Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With
Azacitidine for Newly Diagnosed Acute Myeloid Leukemia[J].J Clin Oncol，2021，39（1）：57-65.
[21]ROBOZ G J，DINARDO C D，STEIN E M，et al.Ivosidenib induces deep durable remissions in patients with newly diagnosed
IDH1-mutant acute myeloid leukemia[J].Blood，2020，135（7）：463-471.
[22]de BOTTON S，MONTESINOS P，SCHUH A C，et al.Enasidenib vs conventional care in older patients with late-stage mutant-IDH2
relapsed/refractory AML：a randomized phase 3 trial[J].Blood，2023，141（2）：156-167.
[23]杨君义，接贵涛.治疗急性髓系白血病新药：Hedgehog 信号通路抑制剂 glasdegib[J].中国新药与临床杂志，2019，38（10）：
589-591.
[24]CORTES J E，HEIDEL F H，HELLMANN A，et al.Randomized comparison of low dose cytarabine with or without glasdegib in
patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome[J].Leukemia，2019，33（2）：379-389.
[25]CORTES J E，DOMBRET H，MERCHANT A，et al.Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid
leukemia：BRIGHT AML 1019 Phase III trials[J].Future Oncology，2019，15（31）：3531-3545.
[26]WEI A H，STRICKLAND S J，HOU J Z，et al.Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients
With Acute Myeloid Leukemia：Results From a Phase Ib/II Study[J].J Clin Oncol，2019，37（15）：1277-1284.
[27]DINARDO C D，JONAS B A，PULLARKAT V，et al.Azacitidine and Venetoclax in Previously Untreated Acute Myeloid
Leukemia[J].The New England journal of medicine，2020，383（7）：617-629.
[28]王小玲，王研，吕国庆，等.BCL-2 抑制剂维奈克拉——革新急性髓系白血病的治疗格局[J].中国临床研究，2023，36（08）：
1247-1251.
[29]颜春霞，王信峰，杨力，等.Bcl-2 抑制剂维奈克拉联合去甲基化药物治疗老年急性髓系白血病 8 例效果观察[J].交通医学，
2022，36（05）：515-516.
[30]LANCET J E，UY G L，NEWELL L F，et al.CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with
newly diagnosed high-risk or secondary acute myeloid leukaemia：5-year results of a randomised，open-label，multicentre，phase 3
trial[J].The Lancet.Haematology，2021，8（7）：e481-e491.
[31]UY G L，PULLARKAT V A，BARATAM P，et al.Lower-intensity CPX-351 + venetoclax for patients with newly diagnosed AML who
are unfit for intensive chemotherapy[J].Journal of clinical oncology，2022，40（16_suppl）：7031.
[32]SWAMINATHAN M ， CORTES J E.Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid
leukemia[J].Therapeutic Advances in Hematology，2023，14：413856005.
[33]LAMBERT J，PAUTAS C，TERRÉ C，et al.Gemtuzumab ozogamicin for de novo acute myeloid leukemia：final efficacy and safety
updates from the open-label，phase III ALFA-0701 trial[J].Haematologica（Roma），2019，104（1）：113-119.
[34]ARAIN S，CHRISTIAN S，PATEL P R，et al.Safety and efficacy of gemtuzumab ozogamicin and venetoclax in patients with relapsed
or refractory CD33+ acute myeloid leukemia：A phase Ib study.[J].Journal of Clinical Oncology，2020，38（15_suppl）：S7566.
[35]SALLMAN D A，AL MALKI M，ASCH A S，et al.Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab
combined with azacitidine in MDS and AML patients：Phase Ib results.[J].Journal of Clinical Oncology，2020，38（15_suppl）：7507.
[36]DAVER N G，VYAS P，KAMBHAMPATI S，et al.Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab
combined with azacitidine in frontline TP53m AML patients：Phase 1b results[J].Journal of clinical oncology，2022，40（16_suppl）：7020.
[37]GALLAZZI M，UCCIERO M A M，FARACI D G，et al.New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute
Myeloid Leukemia and Myelodysplastic Syndromes[J].International Journal of Molecular Sciences，2022，23（14）：7542.
[38]de LEEUW D C，OSSENKOPPELE G J，JANSSEN J J W M.Older Patients with Acute Myeloid Leukemia Deserve Individualized
Treatment[J].Current Oncology Reports，2022，24（11）：1387-1400.
(12 摘要 Views, 25 PDF Downloads)
Refbacks
- 当前没有refback。